Edwards Lifesciences (EW) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Edwards Lifesciences (EW) PT Lowered to $114 at Stifel, 'Buy' Kept
October 26, 2016 9:20 AM EDTStifel analyst Rick Wise lowered his price target on Edwards Lifesciences (NYSE: EW) to $114.00 (from $122.00) following results but maintained a Buy rating.
Wise commented, "While roughly matching both our projections and company guidance, EW's 3Q sales results -- specifically the critical THVT (Transcatheter Heart Therapy) franchise -- fell short of Street expectations by ~$15M (or 4%). Already down in the aftermarket, EW shares undoubtedly will trade lower tomorrow as well, in our view. Despite this shortfall relative to... More
BTIG Sets New PT of $100 on Edwards Lifesciences (EW); Reports Slight Q3 Miss Amid Lofty Expectations
October 26, 2016 8:57 AM EDTBTIG affirms Edwards Lifesciences (NYSE: EW) with a Buy rating and sets a price target of $110 on the stock following Q3 results.
The firm commented today: Expectations were lofty after multiple beats including Q2 THVs that blew away expectations. We and most others... More
